FATE THERAPEUTICS INC Logo

FATE THERAPEUTICS INC

Develops off-the-shelf iPSC cell therapies for cancer and autoimmune diseases.

FATE | NDAQ

Overview

Corporate Details

ISIN(s):
US31189P1021
LEI:
Country:
United States of America
Address:
12278 SCRIPPS SUMMIT DRIVE, 92131 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing first-in-class cellular immunotherapies for cancer and autoimmune diseases. The company utilizes its proprietary induced pluripotent stem cell (iPSC) platform to advance a pipeline of universal, "off-the-shelf" cell product candidates. These multiplexed-engineered therapies are designed to overcome key manufacturing and commercial limitations of conventional cell therapies. By incorporating novel synthetic controls of cell function, Fate's product candidates are intended to deliver multiple therapeutic mechanisms, aiming to make life-changing cell therapies routine and accessible for patients with life-threatening diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all FATE THERAPEUTICS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for FATE THERAPEUTICS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for FATE THERAPEUTICS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea 228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea 066830
Genprex, Inc. Logo
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America GNPX
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway GENT
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America GERN
GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America GHRS
GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea 358570
GILEAD SCIENCES, INC. Logo
Develops innovative medicines for life-threatening diseases in virology, oncology & inflammation.
United States of America GILD
GlaxoSmithKline PLC Logo
A biopharmaceutical company developing vaccines and specialty medicines to prevent and treat disease.
United Kingdom GSK

Talk to a Data Expert

Have a question? We'll get back to you promptly.